FDA To Hold Final Assessment Of The Program For Enhanced Review Transparency And Communication In The Biosimilar User Fee Act - Food, Drugs, Healthcare, Life Sciences
Tomorrow, March, 22, 2022, the FDA will host a public meeting entitled "Final Assessment of the Program for Enhanced Review Transparency and Communication in in the Biosimilar User Fee Act."
Source: mondaq.com